Banking

How Covid Vaccines Could Push IBD Stock Of The Day Avantor Even Higher

Avantor Inc

Avantor Inc

AVTR


$1.60


5.02%


How Covid Vaccines Could Push IBD Stock Of The Day Avantor Even Higher28%

IBD Stock Analysis

  • Shares forming a flat base with a buy point currently at 34.09
  • Stock broke downward trend, now above 50-day and 10-week
  • Composite Rating stands at 95 out of best-possible score of 99
How Covid Vaccines Could Push IBD Stock Of The Day Avantor Even Higher

Composite Rating

How Covid Vaccines Could Push IBD Stock Of The Day Avantor Even Higher

Industry Group Ranking

How Covid Vaccines Could Push IBD Stock Of The Day Avantor Even Higher

Emerging Pattern

How Covid Vaccines Could Push IBD Stock Of The Day Avantor Even Higher

Flat Base

* Not real-time data. All data shown was captured at
1:08PM EDT on
06/10/2021.

Avantor (AVTR) is the IBD Stock Of The Day as shares shake off short-term resistance. Avantor stock is now eyeing a fresh breakout.




X



The company recently reported a “solid start” to 2021, says Evercore ISI analyst Vijay Kumar. First-quarter sales grew by a double-digit percentage and adjusted earnings more than doubled. Meanwhile, Covid vaccines could offer further upside for Avantor, which provides chemicals and tools necessary for drug development.

“We had some robust feedback with Bulls pointing to sequential revenue acceleration (with one fewer selling day), a conservative guide and more than 10% (earnings per share) raise providing cause for cheer,” Kumar said in a note to clients.

In afternoon trading on the stock market today, Avantor stock popped 5% to close at 33.47.

Avantor Stock: Diversified Tools Provider

Avantor doesn’t just provide chemicals and tools for drugmakers. The Fortune 500 company also has customers in the health care, education, government, advanced technologies and materials industries.

Its biggest geographical segment is the Americas. But in the first quarter, the best growth came from its smallest region — Asia, Middle East and Africa. Sales in that geographical segment surged 27.2% organically to $100 million. On a strict as-reported basis, sales popped 32%.

Evercore’s Kumar reiterated his outperform rating on Avantor stock following the earnings report.

Avantor could enjoy a tailwind from booster and pediatric Covid vaccines. Further, the company is planning to finish its acquisition of GmbH, a consumables provider, in the third quarter. Also, Avantor recently said it would buy RIM Bio, a China-based maker of bioprocess bags and assembly tools.

Shares Break Short-Term Resistance

Following the latter acquisition announcement, CFRA Research analyst Sel Hardy initiated coverage of Avantor stock with a buy rating.

“We think Avantor shares offer an attractive entry point at current valuations as we see healthy growth thanks to a diverse product and services portfolio, a solid recurring revenue stream and long-term existing relationships with a global client base,” he said in a note.

Meanwhile, Avantor stock is forming a flat base with a buy point at 34.09, MarketSmith.com research shows.

On Thursday, Avantor stock broke through a downward-sloping trend line, and added some room above its 50-day moving average. It was also busting through short-term resistance around 32.50.

Also bullish, Avantor stock has a strong Composite Rating of 95 out of a best-possible 99, according to IBD Digital. That puts shares in the top 5% in terms of fundamental and technical growth measures.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

Moderna, BioNTech Dive On Possible Tie Between Covid Vaccines, Heart Condition

Biogen Stock Rockets To Record High On Alzheimer’s Drug Approval; 5 Things To Know

Profit From Short-Term Trends With SwingTrader

Learn How To Time The Market With IBD’s ETF Market Strategy

Watch IBD’s Investing Strategies Show For Actionable Market Insights


Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Check Also
Close
Back to top button